World's leading insulin manufacturers confirm they will continue working on Russian market - Russian Health Ministry

MOSCOW. March 10 (Interfax) - The world's leading insulin manufacturers will continue supplying their products to the Russian market, and the supply of popular imported insulin products in Russian pharmacy chains is practically the same as last year's supply, the Russian Health Ministry's press service said.

"The main global insulin manufacturers have confirmed in writing that they will continue working on the Russian market and will continue supplies," the ministry said in a report on Thursday.

The supply of the most popular imported insulin products such as NovoRapid, Fiasp, and Humalog in Russian manufacturers' and distributors' warehouses and in pharmacy chains is now practically the same as the total supply to Russia in 2021, the report said, citing data from monitoring conducted by the Russian Federal Service for Surveillance in Healthcare (Roszdravnadzor) .

The production and launch of Russian insulin in civilian turnover are also going according to plan, the Russian Health Ministry said.

"In this regard, the supply of medications to patients with Type 1 diabetes does not cause alarm. All patients who need insulin can get medications for free with a doctor's prescription," the report said.

The supply of medications is a priority and is under constant control of the Russian Health Ministry and Roszdravnadzor, the press service said.